A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China
Latest Information Update: 08 Jul 2025
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 02 Sep 2024 Planned End Date changed from 29 Jul 2026 to 4 Aug 2026.
- 02 Sep 2024 Planned primary completion date changed from 29 Jul 2026 to 4 Aug 2026.
- 02 Sep 2024 Status changed from not yet recruiting to recruiting.